PNC

NYSE:PNC

PNC Financial Services Group

Add to Watchlist
  • Stock

160.99

+0.19%

−40.70

USD last updated 25/08 01:54:40

Last Close

201.69

22/08 22:30

Market Cap

65.38B

Beta: 1.10

Volume Today

2.00M

Avg: 4.38M

PE Ratio

9.34

PFCF: 5.07

Dividend Yield

4.22%

Payout:34.28%

AlphaQuest LLC increased its stake in The PNC Financial Services Group by 320.4%, making it the fund's largest holding worth $5.18 million. The company reported strong quarterly earnings of $3.85 per share, exceeding estimates, with $3.01 billion in revenue and a 4.6% year-over-year growth. PNC raised its quarterly dividend to $1.70 per share, yielding 3.5%, up from $1.60. The company has a market capitalization of $79.39 billion, a PE ratio of 13.79, and a dividend payout ratio of 46.51%. Several institutional investors also adjusted their positions in PNC during the first and fourth quarters. Wall Street analysts have revised price targets and ratings, with Oppenheimer upgrading to 'outperform' and setting a $238.00 target, while MarketBeat reports a consensus rating of 'Moderate Buy' and a target price of $214.17.

marketbeat.com

Integrated Investment Consultants LLC significantly reduced its holdings in Shell PLC Unsponsored ADR by 81.2% in the first quarter, now owning shares worth approximately $270,000. Other institutional investors, including Brighton Jones LLC, Barclays PLC, Allspring Global Investments Holdings LLC, PNC Financial Services Group Inc., and Merit Financial Group LLC, have also adjusted their positions in the energy company. Shell reported strong quarterly earnings of $1.42 per share, exceeding expectations, with revenue of $66.44 billion and a net margin of 4.93%. The company announced a $3.50 billion share buyback program and a quarterly dividend of $0.716 per share, resulting in an annualized dividend of $2.86 and a 3.9% yield. Analyst ratings have shifted, with Santander, Hsbc Global Res, and Sanford C. Bernstein downgrading Shell, while Piper Sandler maintained an 'overweight' rating. The stock currently trades at $73.3170, with a market capitalization of $215.42 billion and a PE ratio of 16.51.

marketbeat.com

Visa has discontinued its U.S. open banking unit, citing increasing tensions with fintech companies over data access and privacy concerns. The move comes amid broader regulatory pressures in Europe and Latin America, where open banking frameworks like PSD2 have enabled greater data sharing between banks and third-party providers. Visa previously partnered with Plaid for data aggregation, investing $5.3 million in 2020, and had a €1.8 million investment in Sweden-based Tink. In the U.S., regulatory scrutiny under the Dodd-Frank Act's Section 1033 has intensified, prompting banks to restrict data sharing with fintechs. Fintechs have responded with countermeasures, including a coordinated campaign by Andreessen Horowitz's Alex Rampell under 'Operation Chokepoint 3.0' to challenge banks' control over financial data. The decision reflects a growing conflict between traditional financial institutions and fintechs over data ownership and interoperability.

financefeeds.com

Invesco Ltd. increased its stake in PTC Therapeutics, Inc. by 178.6% in the first quarter, owning 310,329 shares valued at $15.8 million as of its latest Form 13F filing. Other institutional investors such as Deutsche Bank AG, Connor Clark & Lunn Investment Management Ltd., Westfield Capital Management Co. LP, PNC Financial Services Group Inc., and Natixis Advisors LLC also adjusted their positions in the biopharmaceutical company. PTC Therapeutics reported quarterly earnings of ($0.83) EPS, exceeding estimates of ($1.07), with a 35.65% net margin and revenue of $178.88 million, down 4.2% year-over-year. The company set FY 2025 EPS guidance, with analysts forecasting a -4.52 EPS. CEO Matthew B. Klein and CFO Pierre Gravier sold shares, reducing their personal holdings by 3.08% and 3.38% respectively. Research firms such as Barclays, Royal Bank of Canada, JPMorgan Chase & Co., and Cowen issued updated ratings, with an average rating of 'Moderate Buy' and an average target price of $69.15. PTC Therapeutics develops treatments for rare disorders, including Translarna, Emflaza, Upstaza, Tegsedi, Waylivra, and Evrysdi, for patients in the U.S. and internationally.

defenseworld.net

Invesco Ltd. reduced its stake in Franklin BSP Realty Trust, Inc. (FBRT) by 0.7% in the first quarter, selling 7,948 shares and holding 1,129,180 shares worth $14.386 million. Other hedge funds and institutional investors also adjusted their positions, with GAMMA Investing LLC increasing its holdings by 1,683.5%, PNC Financial Services Group Inc. raising its position by 138.1%, and Financial Gravity Asset Management Inc. acquiring a new stake valued at $128,000. The company reported a market capitalization of $931.57 million, a dividend yield of 12.5%, and a payout ratio of 144.90%. Brokerage firms such as JMP Securities and Jones Trading issued updated ratings and price targets, with a consensus 'Buy' rating and an average price target of $14.88. Franklin BSP Realty Trust is a self-managed real estate investment trust (REIT) that earns income from adjustable-rate mortgage (ARM) securities issued by government-sponsored enterprises like Fannie Mae, Freddie Mac, and Ginnie Mae.

defenseworld.net

    Description

    The PNC Financial Services Group, Inc. operates as a diversified financial services company in the United States. The company's Retail Banking segment offers checking, savings, and money market accounts, as well as certificates of deposit; residential mortgages, home equity loans and lines of credit, auto loans, credit cards, education loans, and personal and small business loa...Show More

    Earnings

    Earnings per Share (Estimate*)

    -2-112342017-01-132019-01-162021-01-152023-01-182025-01-21

    Revenue (Estimate*)

    1B2B3B4B5B6B2017-01-132019-01-162021-01-152023-01-182025-01-21

    *Estimate based on analyst consensus